Skip to main content
SpringerLink
Log in

Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells

  • Original Article
  • Cisplatin, Modulation, Drug Resistance, Human Tumor Cells
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The aim of this study was to examine whether resistance to cisplatin [cis-diamminedichloroplatinum (II)] (CDDP) could be overcome by amphotericin B, cyclosporin A and aphidicolin in two sublines of human larynx carcinoma HEp2 cells. The sensitivity of parental and cisplatin-resistant CA3 and CK2 cells to amphotericin B, cyclosporin A and aphidicolin, and also the effects of these drugs (given in maximal nontoxic concentrations) on cisplatin sensitivity were determined by clonogenic survival assay. CA3 ad CK2 cells were sensitive to amphotericin B, and resistant to cyclosporin A and aphidicolin, compared with their parental cells. Amphotericin B increased cisplatin toxicity 2-fold in CA3 cells and 2.7-fold in CK2 cells, while it had no effect in parental HEp2 cells. Cyclosporin A did not influence the sensitivity of examined cells to cisplatin. The sensitizing effect of aphidicolin was more obvious in cisplatin-resistant cells. Cisplatin toxicity was increased by aphidicolin: 1.5-fold in HEp2 cells, 2-fold in CA3 cells, and 1.9-fold in CK2 cells. Therefore, the resistance to cisplatin in human larynx carcinoma CA3 and CK2 cells can be partially reversed by amphotericin B and aphidicolin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andrews PA (1992) Mechanisms of acquired resistance to cisplatin. In: Ozols RF, Goldstien LJ (eds) Drug resistance. Kluwer Academic, Boston, p 1

    Google Scholar 

  2. Baldari CT, Macchia G, Heguy A, Melli M, Telford JL (1991) Cyclosporin A blocks calcium-dependent pathways of gene activation. J Biol Chem 266: 19103

    CAS  PubMed  Google Scholar 

  3. Beketic-Oreskovic L, Osmak M Jaksic M (1994) Human larynx carcinoma cells resistant tocis-diamminedichloroplatinum (II): mechanisms involved in the resistance. Neoplasma 41: 161

    Google Scholar 

  4. Calsou P, Salles B (1993) Role of DNA repair in the mechanisms of cells resistance to alkylating agents and cisplatin. Cancer Chemother Pharmacol 32: 85

    Article  CAS  PubMed  Google Scholar 

  5. Chao CC-K, Lee YL, Lin Chao S (1991) Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant tocis-diamminedichloroplatinum (II). Cancer Res 51: 601

    CAS  PubMed  Google Scholar 

  6. Coune A (1988) Amphotericin B as a potentiation agent to cytotoxic chemotheraphy. Eur J Cancer Clin Oncol 24: 117

    Article  CAS  PubMed  Google Scholar 

  7. Creissen DM, Hill CK (1991) A uv-sensitive Chinese hamster lung fibroblast cell line (V79/UC) with a possible defect in DNA polymerase activity is deficient in DNA repair. Radiation Res 125: 306

    Article  CAS  PubMed  Google Scholar 

  8. Damia G, Tagliabue G, Zucchetti M, Davoli E, Sessa C, Cavalli F, D'Incalci M (1992) Activity of aphidicolin glycianate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol 30: 459

    Article  CAS  PubMed  Google Scholar 

  9. Demke WCM, Shellard SA, Fichtinger-Schepman AMJ, Hill BT (1991) Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycianate in two logarithmically-growing ovarian tumour cells linesin vitro. Carcinognesis 12: 525

    Article  Google Scholar 

  10. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR (1991) Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352: 803

    Article  CAS  PubMed  Google Scholar 

  11. Foxwell BM, Mackie A, Ling V, Ryffel B (1989) Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36: 543

    CAS  PubMed  Google Scholar 

  12. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin. A review. Br J Cancer 67: 1171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hong WS, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K, Twentyman PR (1988) Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer 41: 462

    Article  CAS  PubMed  Google Scholar 

  14. Hu XF, Martin TJ, Bell DR, Luise M, Zalcberg JR (1990) Combination use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953

    CAS  PubMed  Google Scholar 

  15. Ikegani S, Taguchi T, Ohashi M, Oguro M, Nagana H, Mano Y (1987) Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase α. Nature 257: 458

    Google Scholar 

  16. Johnson SW, Ozols RF, Hamilton TC (1993) Mechanisms of drug resistance in ovarian cancer. Cancer 71: 644

    Article  CAS  PubMed  Google Scholar 

  17. Kashani-Sabet M, Wang W, Scanlon KJ (1990) Cyclosporin A supresses cisplatin induces c-fos gene expression in ovarian carcinoma cells. J Biol Chem 265: 11285

    CAS  PubMed  Google Scholar 

  18. Katz EJ, Andrews PA, Howell SB (1990) The effect of polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun 2: 129

    Google Scholar 

  19. Krishan A, Sauerteig A, Gordon K (1985) Effect of amphotericin B on transport in P388 cells. Cancer Res 45: 4907

    Google Scholar 

  20. Lai G, Ozols RF, Smyth JF, Young RC, Hamilton TC (1988) Enhanced Repair as a mechanism of resistance tocis-diamminedichloroplatinum (II). Biochem Pharmacol 37: 4597

    Article  CAS  PubMed  Google Scholar 

  21. Lum BL, Kaubich S, Yahanda AM, Adler KM, Jew L, Ehson MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635

    CAS  PubMed  Google Scholar 

  22. Masuda H, Ozols RF, Lai G-M, Fojo A, Rothenberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of a acquired resistance tocis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48: 5713

    CAS  PubMed  Google Scholar 

  23. Masuda H, Tanaka T, Matsuda H, Kusaba I (1990) Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant tocis-diamminedichloroplatinum (II). Cancer Res 50: 1863

    CAS  PubMed  Google Scholar 

  24. Masuda H, Tanaka T, Kido A, Kusaba I (1991) Potentiation of cisplatin against sensitive and resistant human ovarian cancer cell lines by amphotericin B. Cancer J 4: 119

    CAS  Google Scholar 

  25. Masuda H, Tanaka T, Matsushima S, Kusaba I (1992) Selective potentiation of cisplatin in combination with amphotericin B and aphidicolin against human ovarian cancer cell line. Cancer J 5: 96

    CAS  Google Scholar 

  26. Mirzaynas R, Andrais B, Paterson MC (1992) Synergistic effect of aphidicolin and 1-β-D-arabinofuranosylcytosine on the repair of γ-ray-induced DNA damage in normal human fibroblasts. Int J Radiat Biol 62: 417

    Article  Google Scholar 

  27. Mitchell JB, Cook J, DeGraaf W, Glatstein E, Russo A (1989) Glutathione modulation in cancer treatment: will it work? (keynote address). Int J Radiat Oncol Biol Phys 16: 1289

    Article  CAS  PubMed  Google Scholar 

  28. Morikage T, Bungo M, Inomata M, Yoshida M, Ohmori T, Fujiwara J, Nishio K, Saijo N (1991) Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J Cancer Res 82: 747

    Article  CAS  PubMed  Google Scholar 

  29. Morikage T, Ohmori T, Nishio K, Fujiwara Y, Takeda Y, Saijo N (1992) Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res 53: 3302

    Google Scholar 

  30. O'Dwyer PJ, Moyer JD, Suffness M, Harrison SD Jr, Cysyc R, Hamilton TC, Plowman J (1994) Antitumor activity and biochemical effects of aphidicolin glycianate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res 54: 724

    PubMed  Google Scholar 

  31. Osmak M (1992) Collateral resistance or sensitivity of human larynx carcinoma HEp2 cells resistant tocis-diamminedichloroplatinum (II) or vincristine sulfate. Neoplasma 39: 197

    CAS  PubMed  Google Scholar 

  32. Osmak M, Beketic-Oreskovic L, Matulic M, Soric J (1993) Resistance of human larynx carcinoma cells to cisplatin, gamma irradiation and methotrexate do not involve overexpression of c-myc or c-Ki-ras oncogenes. Mutat Res Lett 303: 113

    Article  CAS  Google Scholar 

  33. Ozols RF, Hogan WM, Grotzinger KR, McKoy W, Young RC (1983) Effects of amphotericin B or Adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and L1210 leukemia. Cancer Res 43: 959

    CAS  PubMed  Google Scholar 

  34. Presant CA, Carr D (1980) Ampnotericin B (Fungisone) enhancement of nitrogen mustard uptake by human tumor cells. Biochem Biophys Res Commun 93: 1067

    Article  CAS  PubMed  Google Scholar 

  35. Scanlon KJ, Kashani-Sabet M, Sowers LC (1989) Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 4: 269

    Google Scholar 

  36. Scanlon KJ, Wang W, Han H (1990) Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat Rev 17: 27

    Article  CAS  PubMed  Google Scholar 

  37. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T (1991) Cisplatin resistance in human cancers. Pharmac Ther 52: 385

    Article  CAS  Google Scholar 

  38. Sculier JP, Coune A, Meunier F, Brassine C, Laduron C, Hallaert C, Collette N, Heymans C, Klastersky J (1988) Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 24: 527

    Article  CAS  PubMed  Google Scholar 

  39. Sessa C, Zucchetti M, Davoli E, Califano R, Cavalli F, Frustaci S, Gumbrell L, Sulkes A, Winograd B, D'Incalci M (1991) Phase I and clinical pharmacological evaluation of aphidicolin glycianate. J Natl Cancer Inst 83: 1160

    Article  CAS  PubMed  Google Scholar 

  40. Shoji Y, Fisher MH, Perisamy A, Herman B, Juliano RL (1991) Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms. Cancer Lett 57: 209

    Article  CAS  PubMed  Google Scholar 

  41. Stewart DJ, Evans WK (1989) Non-chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treat Rev 16: 1

    Article  CAS  PubMed  Google Scholar 

  42. Timmer-Boscha H, Mulder NH, De Vriaes EGE (1992) Modulation ofcis-diamminedichloroplatinum (II) resistance: a review. Br J Cancer 66: 227

    Article  Google Scholar 

  43. Vayuvegula B, Slater L, Medor J, Gupta S (1988) Correlation of altered plasm membrane potentials. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia. Cancer Chemother Pharmacol 22: 163

    Article  CAS  PubMed  Google Scholar 

  44. Vertut-Croquin A, Brajtburg J, Medoff G (1986) Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea against the human promyelocytic leukemia cell line HL-60. Cancer Res 46: 6054

    CAS  PubMed  Google Scholar 

  45. Waxman DJ (1990) GlutathioneS-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy—a review. Cancer Res 50: 6449

    CAS  PubMed  Google Scholar 

  46. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10: 1624

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 41000, Zagreb, Croatia

    Lidija Beketic-Oreskovic & Maja Osmak

Authors
  1. Lidija Beketic-Oreskovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maja Osmak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beketic-Oreskovic, L., Osmak, M. Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells. Cancer Chemother. Pharmacol. 35, 327–333 (1995). https://doi.org/10.1007/BF00689453

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689453

Key words

Search

Navigation